Preventive Effects of Aspirin on Cardiovascular Complications in Prostate Cancer Cases after Endocrinotherapy

Abstract

<br/><b>Objective</b>: To explore the preventive effect of aspirin on the cardiovascular complications in prostate cancerafter endocrinotherapy. Materials and <br/><b>Methods</b>: A total of 92 patients with prostate cancer were divided intoobservation group (n=44) and control group (n=48). The control group was treated with medical castration plusanti-androgenic drugs. Based on the above treatment, the observation group was added aspirin. The follow-upduration was 2 years. The changes of partial prothrombin time (PT), activated partial thromboplastin time(APTT), platelet aggregation rate (PAG), prostate-specific antigen (PSA) and serum testosterone (T) beforeand after treatment as well as incidence of cardiovascular disease were observed. <br/><b>Results</b>: The 2-year survivalrates of patients without cardiovascular disease in observation group and control group were 95.45% (42/44)and 72.92% (35/48), respectively, and significant difference was presented between two groups by comparisonto the survival rates (χ2=8.5453, p=0.0035). There was no statistical significance between two groups as well asbefore and after treatment regarding PT (p>0.05). After treatment, APTT went down and PAG was gradually onthe rise in control group, while PAG down and APTT on the rise increasingly in observation group. Significantdifferences were presented between two groups as well as before and after treatment (p<0.01). Both PSA and Tlevels were decreased significantly in two groups after treatment (p<0.01), but there was no statistical significantbetween two groups (p>0.05). <br/><b>Conclusions</b>: Application of endocrinotherapy in prostate cancer can easily leadto occurrence of cardiovascular disease, but cardiovascular complications can be prevented by aspirin, withoutaffecting the effect of endocrinotherapy.